Histone Deacetylase Inhibitors Impair Glioblastoma Cell Motility and Proliferation
Overview
Authors
Affiliations
Despite being subjected to high-dose chemo and radiotherapy, glioblastoma (GBM) patients still encounter almost inevitable relapse, due to the capability of tumor cells to disseminate and invade normal brain tissues. Moreover, the presence of a cancer stem cell (CSC) subpopulation, already demonstrated to better resist and evade treatments, further frustrates potential therapeutic approaches. In this context, we previously demonstrated that GBM is characterized by a tightly-regulated balance between the β-catenin cofactors TCF1 and TCF4, with high levels of TCF4 responsible for sustaining CSC in these tumors; thus, supporting their aggressive features. Since histone deacetylase inhibitors (HDI) have been reported to strongly reduce TCF4 levels in colon cancer cells, we hypothesized that they could also exert a similar therapeutic action in GBM. Here, we treated primary GBM cultures with Trichostatin-A and Vorinostat, demonstrating their ability to strongly suppress the Wnt-dependent pathways; thus, promoting CSC differentiation and concomitantly impairing GBM cell viability and proliferation. More interestingly, analysis of their molecular effects suggested a prominent HDI action against GBM cell motility/migration, which we demonstrated to rely on the inhibition of the RhoA-GTPase and interferon intracellular cascades. Our results suggest HDI as potential therapeutic agents in GBM, through their action on multiple cancer hallmarks.
The Role of HDAC6 in Glioblastoma Multiforme: A New Avenue to Therapeutic Interventions?.
Spallotta F, Illi B Biomedicines. 2024; 12(11).
PMID: 39595195 PMC: 11591585. DOI: 10.3390/biomedicines12112631.
A Review of Therapeutic Agents Given by Convection-Enhanced Delivery for Adult Glioblastoma.
Rolfe N, Dadario N, Canoll P, Bruce J Pharmaceuticals (Basel). 2024; 17(8).
PMID: 39204078 PMC: 11357193. DOI: 10.3390/ph17080973.
A high-throughput microfabricated platform for rapid quantification of metastatic potential.
Bhattacharya S, Ettela A, Haydak J, Hobson C, Stern A, Yoo M Sci Adv. 2024; 10(33):eadk0015.
PMID: 39151003 PMC: 11328906. DOI: 10.1126/sciadv.adk0015.
Preclinical and clinical advances to overcome hypoxia in glioblastoma multiforme.
Bou-Gharios J, Noel G, Burckel H Cell Death Dis. 2024; 15(7):503.
PMID: 39003252 PMC: 11246422. DOI: 10.1038/s41419-024-06904-2.
On the effects of 30.5 GHz sinusoidal wave exposure on glioblastoma organoids.
Rampazzo E, Persano L, Karim N, Hodgking G, Pinto R, Casciati A Front Oncol. 2024; 14:1307516.
PMID: 38884089 PMC: 11176452. DOI: 10.3389/fonc.2024.1307516.